Verastem (VSTM) Non-Current Assets (2011 - 2026)
Verastem's quarterly Non-Current Assets came in at $24.9 million in Q1 2026, up 255.82% year-on-year from $7.0 million in Q1 2025, and up 8.14% quarter-over-quarter from $23.0 million in Q4 2025.
Verastem has reported Non-Current Assets for 16 years, with the latest figure at $24.9 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets rose 255.82% year-over-year to $24.9 million; the trailing twelve-month figure through Mar 2026 stood at $92.7 million (up 265.14% YoY), and the FY2025 full-year result was $23.0 million, up 250.14% from the prior year.
- Non-Current Assets for Q1 2026 stood at $24.9 million, up from $23.0 million in the prior quarter.
- The five-year high for Non-Current Assets was $24.9 million in Q1 2026, with the low at $1.7 million in Q3 2023.
- Average Non-Current Assets over 5 years is $8.5 million, with a median of $5.9 million recorded in 2024.
- Year-over-year, Non-Current Assets sank 72.25% in 2022 and surged 298.81% in 2025.
- Tracing VSTM's Non-Current Assets over 5 years: stood at $2.2 million in 2022, then soared by 176.88% to $6.0 million in 2023, then increased by 8.96% to $6.6 million in 2024, then soared by 250.14% to $23.0 million in 2025, then gained by 8.14% to $24.9 million in 2026.
- The last three Non-Current Assets figures came in at $24.9 million (Q1 2026), $23.0 million (Q4 2025), and $22.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Verastem | 425.60 Mn | 243.93 Mn | 15.90 Mn | 24.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.90 Mn |
| Dec 31, 2025 | 23.03 Mn |
| Sep 30, 2025 | 22.80 Mn |
| Jun 30, 2025 | 21.99 Mn |
| Mar 31, 2025 | 7.00 Mn |
| Dec 31, 2024 | 6.58 Mn |
| Sep 30, 2024 | 5.72 Mn |
| Jun 30, 2024 | 6.10 Mn |
| Mar 31, 2024 | 5.87 Mn |
| Dec 31, 2023 | 6.04 Mn |
| Sep 30, 2023 | 1.67 Mn |
| Jun 30, 2023 | 1.80 Mn |
| Mar 31, 2023 | 1.98 Mn |
| Dec 31, 2022 | 2.18 Mn |
| Sep 30, 2022 | 2.34 Mn |
| Jun 30, 2022 | 2.53 Mn |
| Mar 31, 2022 | 2.71 Mn |
| Dec 31, 2021 | 2.92 Mn |
| Sep 30, 2021 | 3.12 Mn |
| Jun 30, 2021 | 9.13 Mn |
| Mar 31, 2021 | 9.22 Mn |
| Dec 31, 2020 | 9.41 Mn |
| Sep 30, 2020 | 29.22 Mn |
| Jun 30, 2020 | 53.94 Mn |
| Mar 31, 2020 | 59.51 Mn |
| Dec 31, 2019 | 60.09 Mn |
| Sep 30, 2019 | 25.64 Mn |
| Jun 30, 2019 | 26.20 Mn |
| Mar 31, 2019 | 26.77 Mn |
| Dec 31, 2018 | 23.98 Mn |
| Sep 30, 2018 | 24.43 Mn |
| Jun 30, 2018 | 2.48 Mn |
| Mar 31, 2018 | 2.38 Mn |
| Dec 31, 2017 | 2.00 Mn |
| Sep 30, 2017 | 1.94 Mn |
| Jun 30, 2017 | 2.09 Mn |
| Mar 31, 2017 | 2.24 Mn |
| Dec 31, 2016 | 2.33 Mn |
| Sep 30, 2016 | 1.73 Mn |
| Jun 30, 2016 | 1.89 Mn |
| Mar 31, 2016 | 2.03 Mn |
| Dec 31, 2015 | 2.25 Mn |
| Sep 30, 2015 | 2.49 Mn |
| Jun 30, 2015 | 2.95 Mn |
| Mar 31, 2015 | 7.13 Mn |
| Dec 31, 2014 | 3.33 Mn |
| Sep 30, 2014 | 3.41 Mn |
| Jun 30, 2014 | 7.78 Mn |
| Mar 31, 2014 | 9.14 Mn |
| Dec 31, 2013 | 23.31 Mn |
| Sep 30, 2013 | 31.42 Mn |
| Jun 30, 2013 | 21.67 Mn |
| Mar 31, 2013 | 18.53 Mn |
| Dec 31, 2012 | 35.84 Mn |
| Sep 30, 2012 | 51.55 Mn |
| Jun 30, 2012 | 66.47 Mn |
| Mar 31, 2012 | 69.15 Mn |
| Dec 31, 2011 | 11.10 Mn |